- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.11. | Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates | 27 | GlobeNewswire (Europe) | -- Lung cancer programs progressing with interim data updates expected in Q4 2025 -- -- Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected in the second half of 2026 --... ► Artikel lesen | |
| 05.11. | GENELUX Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 21.10. | Lake Street Capital Markets initiates Genelux stock with Buy rating | 3 | Investing.com | ||
| 03.09. | GENELUX Corp - 8-K, Current Report | 5 | SEC Filings | ||
| 08.08. | Genelux GAAP EPS of -$0.20 beats by $0.02 | 2 | Seeking Alpha | ||
| 07.08. | GENELUX Corp - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 07.08. | Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates | 109 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter... ► Artikel lesen | |
| GENELUX Aktie jetzt für 0€ handeln | |||||
| 23.07. | Genelux stock maintains Buy rating at H.C. Wainwright amid sector news | - | Investing.com | ||
| 23.07. | Genelux: H.C. Wainwright bestätigt Kaufempfehlung trotz Rückschlag bei Konkurrenz | 2 | Investing.com Deutsch | ||
| 21.07. | Lucid Capital Markets initiates Genelux stock with Buy rating, $10 target | 1 | Investing.com | ||
| 07.07. | Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development | 189 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Eric Groen as General... ► Artikel lesen | |
| 06.05. | Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates | 160 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter... ► Artikel lesen | |
| 28.03. | Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | 202 | GlobeNewswire (Europe) | - Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer - - Positive Preliminary Phase 1b/2... ► Artikel lesen | |
| 25.03. | Genelux Corporation: Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer | 552 | GlobeNewswire (Europe) | - Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced... ► Artikel lesen | |
| 03.02. | Genelux Corporation Announces New Chief Financial Officer | 196 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has joined the... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INFLARX | 1,020 | -2,49 % | InflaRx reports positive phase 2 results for HS and CSU treatments | ||
| REDHILL BIOPHARMA | 1,110 | +9,36 % | RedHill Biopharma Receives Nasdaq Staff Determination Notification | On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the minimum... ► Artikel lesen | |
| IMMUNIC | 0,616 | +3,01 % | EQS-News: Immunic AG: Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Issuer: Immunic AG
/ Key word(s): 9 Month figures
Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
13.11.2025 / 12:30 CET/CEST
The... ► Artikel lesen | |
| CURIS | 0,980 | -1,51 % | Curis, Inc.: Curis Provides Third Quarter 2025 Business Update | Management to host conference call and webcast today at 4:30 p.m. ET
LEXINGTON, Mass., Nov. 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 1,690 | +0,12 % | BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements | NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in... ► Artikel lesen | |
| ESPERION | 3,190 | +15,75 % | Esperion Therapeutics, Inc.: Esperion Partner Otsuka Launches NEXLETOL in Japan for the Treatment of Hypercholesterolemia | - Company to Receive $90 Million Total Payment - - Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL - ANN ARBOR, Mich., Nov.... ► Artikel lesen | |
| CYBIN | 5,200 | +1,96 % | Canaccord Genuity lowers Cybin stock price target to $45 on dilution | ||
| KARYOPHARM | 4,720 | -2,88 % | Karyopharm Therapeutics Inc.: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NEWTON, Mass., Nov. 3, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies... ► Artikel lesen | |
| BIOLINERX | 2,790 | +8,56 % | BioLineRx Ltd.: BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 1,500 | -1,96 % | Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results | Company to host conference call and webcast today at 8:00 a.m. EST
CARMIEL, Israel, Nov. 13, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:... ► Artikel lesen | |
| EDESA BIOTECH | 1,440 | -4,64 % | Edesa Biotech, Inc.: Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study | Study met primary and secondary endpointsParidiprubart demonstrated a relative reduction in the risk of death of 25%Treatment provided patients with clinically meaningful improvement in survival and... ► Artikel lesen | |
| BRIACELL THERAPEUTICS | 7,600 | +2,01 % | BriaCell to present positive cancer treatment data at breast cancer symposium | ||
| SAGIMET BIOSCIENCES | 6,100 | +5,17 % | Sagimet Biosciences Inc.: Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates | Phase 1 clinical trial to evaluate the PK of a combination of denifanstat and resmetirom ongoing with data readout expected 1H 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567... ► Artikel lesen | |
| CINGULATE | 3,690 | +4,53 % | Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Industry Veteran Bryan Downey Named Chief Commercial Officer NDA Accepted with May 2026 PDUFA Date Commercial Supply Agreement Executed KANSAS CITY, Kan., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cingulate... ► Artikel lesen | |
| VERRICA PHARMACEUTICALS | 4,560 | +10,68 % | Verrica Pharmaceuticals announces $50M PIPE financing |
Das Unternehmen GENELUX CORPORATION kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 5,290 Euro und damit +3,73 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENELUX CORPORATION finden Sie auf Wallstreet Online.